BCL11A Is Oncogenic and Predicts Poor Outcomes in Natural Killer/T-Cell Lymphoma

The current treatment for natural killer/T-cell lymphoma (NKTL) among advanced/relapsed patients is unsatisfying, thereby highlighting the need for novel therapeutic targets. B‐cell chronic lymphocytic leukemia/lymphoma 11 A (BCL11A), as a transcription factor, is oncogenic in several neoplasms. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Hongyun, Li, Chun, Feng, Wei, Yue, Jianjun, Song, Jingfang, Peng, Aizhi, Wang, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311857/
https://www.ncbi.nlm.nih.gov/pubmed/32625084
http://dx.doi.org/10.3389/fphar.2020.00820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311857/
https://www.ncbi.nlm.nih.gov/pubmed/32625084
http://dx.doi.org/10.3389/fphar.2020.00820

Ejemplares similares